An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors

Mayo Clinic

Status: Completed

Conditions: EGFR Genes; ALK Genes; Cancer of Lung; Pulmonary Cancer; Lung Cancer; Lung Neoplasm; Adenocarcinoma of Lung

Study type: Observational

Funder types: Other

Identifiers

NCT02616211

14-002084

Details and patient eligibility

About

Patients are asked to participate in this study if they have been diagnosed with a thoracic carcinoma which includes lung cancer and have a gene mutation (alteration in the body's genetic instructions) and after undergoing treatment the cancer has come back, progressed, or shown a partial response on standard treatment.

Full description

In order to improve the treatment outcome for thoracic carcinomas after they become resistant to targeted therapy, the investigator is using tumor biopsies at the time of recurrence for genomic analysis to identify novel somatic changes in critical genes and gene pathways that can potentially be targeted with therapy. The study team is also creating patient-derived xenografts to test drug efficacy and optimize personalized therapy for each patient.

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years or older
• Thoracic carcinoma tumors are positive for any targetable genetic alterations
• Have shown partial or no response, progression or recurrence while on or after gene targeted therapy by CT/PET scan
• Tumor is accessible for biopsy or surgery
• Expected life is 6 months or longer.

Exclusion criteria

• < 18 years
• Not able to communicate in English